← Back to Patent Explorer
US5318768A Expired / Lapsed US ⏱️ 0.0 years remaining

Polymeric x-ray contrast compositions containing an organic crystalline x-ray contrast agent

Assignee: GE Healthcare AS
•
Filing: 1993-02-17
•
Granted: 1994-06-07
•
Expires: 2013-02-17
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising a polymeric material in combination with a divalent cation capable of forming a coating on the gastrointestinal tract and a crystalline contrast agent in a pharmaceutically acceptable carrier; and methods for their use in diagnostic radiology of the gastrointestinal tract.

Inventors

  • 👤 Carl R. Illig
  • 👤 Eugene R. Cooper

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-03 22:55
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/04; A61K49/0433; A61K49/0442; A61K49/0447; A61K49/0461; B; B82; B82Y; B82Y5/00

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 410 words
An x-ray contrast composition designed for depositing a thin, flexible film membrance onto the mucosal lining of the nutrient absorbing inner surface of the intenstine of a patient to form a barrier between said nutrient absorbing inner surface and the content of said intestine, said flexible film membrane to remain bound to said mucosal lining until eliminated by normal cell turnover comprising based on w/v: (a) of from about 0.1 to about 25% of a polymeric material capable of forming a film membrane on the gastrointestinal tract in the pH range of from about 5 to about 8, said polymeric material being selected from the group consisting of anionic polymers carrying negative charges in the ionized form, cationic polymers carrying positive charges in the ionized form, and neutral polymers, said neutral polymers having atoms containing polarizable electrons thereon, selected from the group consisting of oxygen, nitrogen, sulfur, fluoride, chloride, bromide and iodide, in combination with (b) of from about 0.1 to about 20% of a divalent cation to potentiate the binding of said flexible film membrane to said mucosal lining selected from the group consisting of Ca ++ , Mg ++ , Zn ++ and Ba ++ ; and (c) of from about 5 to about 95% of a crystalline contrast agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of from about 0.5 μ to about 100 μ in a pharmaceutically acceptable carrier wherein said crystalline contrast agent is selected from the group consisting of diatrizoic acid, metrizoic acid, iothalamic acid, trimesic acid, urokocic acid, ioxathalamic acid, tetraiodoterephthalic acid, ioxaglic acid, iodipamide, ethyl-3,5-diacetamido-2,4,6-triiodobenzoate, ethyl-2-(3,5-bis(acetylamino)-2,4,6-triiodobenzoyloxy)butyrate, and ethyl(3,5-bis(acetylamino)-2,4,60triiodobenzoyloxy)-acetate; and said surface modifier is selected from the group consisting of a tetrafuctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine, and a compound of the formula ##STR12## wherein ##STR13## L' is a chemical bond, --O--, --S--, --NH--, --CONH-- or --SO 2 NH--; R is a hydophobic substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or a substituted or unsubstituted aryl group; each of R 1 and R 2 independently is hydrogen or an alkyl group having from 1 to 4 carbon atoms; each of a and b independently is 0 or an integer from 1 to 3, provided that the sum of a and b is not greater than 3; and each of x and y independently is an integer from 3 to 7.
Claim 2
Dependent Claim 410 words
An x-ray contrast composition designed for depositing a thin, flexible film membrance onto the mucosal lining of the nutrient absorbing inner surface of the intenstine of a patient to form a barrier between said nutrient absorbing inner surface and the content of said intestine, said flexible film membrane to remain bound to said mucosal lining until eliminated by normal cell turnover comprising based on w/v: (a) of from about 0.1 to about 25% of a polymeric material capable of forming a film membrane on the gastrointestinal tract in the pH range of from about 5 to about 8, said polymeric material being selected from the group consisting of anionic polymers carrying negative charges in the ionized form, cationic polymers carrying positive charges in the ionized form, and neutral polymers, said neutral polymers having atoms containing polarizable electrons thereon, selected from the group consisting of oxygen, nitrogen, sulfur, fluoride, chloride, bromide and iodide, in combination with (b) of from about 0.1 to about 20% of a divalent cation to potentiate the binding of said flexible film membrane to said mucosal lining selected from the group consisting of Ca ++ , Mg ++ , Zn ++ and Ba ++ ; and (c) of from about 5 to about 95% of a crystalline contrast agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of from about 0.5 μ to about 100 μ in a pharmaceutically acceptable carrier wherein said crystalline contrast agent is selected from the group consisting of diatrizoic acid, metrizoic acid, iothalamic acid, trimesic acid, urokocic acid, ioxathalamic acid, tetraiodoterephthalic acid, ioxaglic acid, iodipamide, ethyl-3,5-diacetamido-2,4,6-triiodobenzoate, ethyl-2-(3,5-bis(acetylamino)-2,4,6-triiodobenzoyloxy)butyrate, and ethyl(3,5-bis(acetylamino)-2,4,60triiodobenzoyloxy)-acetate; and said surface modifier is selected from the group consisting of a tetrafuctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine, and a compound of the formula ##STR12## wherein ##STR13## L' is a chemical bond, --O--, --S--, --NH--, --CONH-- or --SO 2 NH--; R is a hydophobic substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or a substituted or unsubstituted aryl group; each of R 1 and R 2 independently is hydrogen or an alkyl group having from 1 to 4 carbon atoms; each of a and b independently is 0 or an integer from 1 to 3, provided that the sum of a and b is not greater than 3; and each of x and y independently is an integer from 3 to 7.
Claim 3
Dependent Claim 70 words
The x-ray contrast composition of claim 1 wherein said anionic polymeric material is a sulfated polysaccharide having the formula: ##STR14## wherein R is 3,6-anhydro-D-galactose ______________________________________ through C-4 to D-galactose; (kappa carrageenan); α-D-galactose units (1-3) linked; (lambda carrageenan);] D-galactose; [3,6-anhydro-D-galactose; (iota carrageenan) D-galactose] 3,6-anhydro-L-galactose [: (Agar-Agar)]; D-galactose [3,6-anhydro-D-galactose; (Furcellaren) D-glucopyranose; (Laminarin sulfate)] Galactan; and [(Galactan sulfate)] Galactosamino-glucuronans [(Chondroitin sulfates);] and M.sup.++ is Mg.sup.++, Ca.sup.++, Zn.sup.++, Ba.sup.++ or a mixture thereof.-- ______________________________________
Claim 4
Dependent Claim 51 words
The x-ray contrast composition of claim 1 wherein said anionic polymeric material is a sulfated, sulfonated or carboxylated synthetic polymer having the formula: ##STR15## wherein R is an aliphatic or aromatic hydrocarbon; and M ++ is Mg ++ , Ca ++ , Zn ++ , Ba ++ or a mixture thereof.
Claim 5
Dependent Claim 27 words
The x-ray contrast composition of claim 1 wherein said cationic polymeric material is selected from the group consisting of: dermatan sulfate, keratosulfate, hyaluronic acid, heparin and chitin.
Claim 6
Dependent Claim 16 words
The x-ray contrast composition of claim 1 wherein said pharmaceutical carrier contains at least one surfactant.
Claim 7
Dependent Claim 62 words
The x-ray contrast formulation of claim 5 wherein said cationic surfactant is selected from the group consisting of cetyltrimethyl ammonium bromide, dodecyl dimethyl ammonium bromide, sodium lauryl sulfate, sodium heptadecyl sulphate, an alkyl benzene sulphonic acid, sodium butylnaphthalene sulfonate, sodium butylnaphthalene, sulphosuccinate, carboxylic esters, carboxylic amides, ethoxylated alkylphenols, ethoxylated aliphatic alcohols, polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters and zwitterionic surfactants.
Claim 8
Dependent Claim 33 words
A method of carrying out x-ray examination of the gastrointestinal tract of a patient, said method comprises the oral or rectal administration to the patient an x-ray contrast composition according to claim 1.

References Cited (Backward Citations)

US2622100A Cited
US2680089A Cited
US2659690A Cited
US2832722A Cited
US3192118A Cited
US4069306A Cited
US4038379A Cited
US4120946A Cited
JPS55127322A Cited
US4692325A Cited
US4588574A Cited
US5019370A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1997-06-06 1997-12-06 1998-06-07 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2001-06-06 2001-12-06 2002-06-07 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2005-06-06 2005-12-06 2006-06-07 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag